当前位置: X-MOL 学术J. Pediatr. Surg. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Comparative Effects on Fetal Hematopoiesis and Placental Inflammation From Mesenchymal and Hematopoietic Stem Cells as Agents of Transamniotic Stem Cell Therapy (TRASCET) in a Syngeneic Model of Intrauterine Growth Restriction
Journal of Pediatric Surgery ( IF 2.4 ) Pub Date : 2024-03-15 , DOI: 10.1016/j.jpedsurg.2024.03.011
Kamila Moskowitzova , Abbie E. Naus , Ina Kycia , Tanya T. Dang , Yash V. Shroff , Emilia Bletsas , Kaitlin Mullin , David Zurakowski , Dario O. Fauza

We compared transamniotic stem cell therapy (TRASCET) using either mesenchymal (MSCs) or hematopoietic (HSCs) stem cells on fetal hematopoiesis in a syngeneic model of intrauterine growth restriction (IUGR). Lewis dams exposed to cycling hypoxia (10.5% O) in late gestation had their fetuses (n = 83) either receiving no intervention (untreated; n = 9), or intra-amniotic injections of either HSCs (HSC; n = 34), MSCs primed to an enhanced anti-inflammatory phenotype (primed-MSC; n = 28), or saline (sham; n = 12). Normal controls (n = 18) were also studied. Complete peripheral blood counts and placental ELISA for inflammation and angiogenesis markers were performed at term. Overall survival from hypoxia was 41% (34/83). Red blood count (RBC), hematocrit (Hct) and hemoglobin levels (Hb) were all significantly decreased from normal in all hypoxia groups. TRASCET with primed-MSC had significantly higher RBC, Hct, and Hb levels than sham (p = 0.01–0.03, pairwise), though not than untreated (which had no surgical blood loss). The HSC group had only significantly higher Hb levels than sham (p = 0.005). TRASCET with primed-MSC had significantly lower levels of placental TNF-α than sham (p = 0.04), but not untreated. MCSs seem more effective than HSCs in enhancing hematopoiesis when used as donor cells for TRASCET in a syngeneic model of IUGR. N/A (animal and laboratory study).

中文翻译:

在子宫内生长受限的同基因模型中,间充质干细胞和造血干细胞作为经羊膜干细胞疗法 (TRASCET) 对胎儿造血和胎盘炎症的比较影响

我们在宫内生长受限(IUGR)同基因模型中比较了使用间充质(MSC)或造血(HSC)干细胞的经羊膜干细胞疗法(TRASCET)对胎儿造血的影响。在妊娠后期暴露于循环缺氧 (10.5% O) 的 Lewis 母鼠的胎儿 (n = 83) 要么不接受干预(未经治疗;n = 9),要么羊膜内注射 HSC (HSC;n = 34),已引发增强抗炎表型的 MSC(已引发的 MSC;n = 28)或生理盐水(假手术;n = 12)。还对正常对照(n = 18)进行了研究。足月时进行完整的外周血计数和胎盘 ELISA 检测炎症和血管生成标记物。缺氧的总生存率为 41% (34/83)。所有缺氧组的红细胞计数(RBC)、血细胞比容(Hct)和血红蛋白水平(Hb)均较正常值显着下降。与假手术相比,经过预处理的 MSC 的 TRASCET 的 RBC、Hct 和 Hb 水平显着高于假手术(p = 0.01-0.03,成对),但并不比未治疗(没有手术失血)高。 HSC 组的 Hb 水平仅显着高于假手术组 (p = 0.005)。与假手术相比,经过预处理的 MSC 的 TRASCET 胎盘 TNF-α 水平显着降低 (p = 0.04),但并非未经治疗。当在 IUGR 同基因模型中用作 TRASCET 的供体细胞时,MCS 在增强造血方面似乎比 HSC 更有效。 N/A(动物和实验室研究)。
更新日期:2024-03-15
down
wechat
bug